These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28281693)

  • 1. Carnosine Attenuates the Development of both Type 2 Diabetes and Diabetic Nephropathy in BTBR ob/ob Mice.
    Albrecht T; Schilperoort M; Zhang S; Braun JD; Qiu J; Rodriguez A; Pastene DO; Krämer BK; Köppel H; Baelde H; de Heer E; Anna Altomare A; Regazzoni L; Denisi A; Aldini G; van den Born J; Yard BA; Hauske SJ
    Sci Rep; 2017 Mar; 7():44492. PubMed ID: 28281693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse.
    Askari B; Wietecha T; Hudkins KL; Fox EJ; O'Brien KD; Kim J; Nguyen TQ; Alpers CE
    Lab Invest; 2014 Aug; 94(8):851-62. PubMed ID: 24955894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carnosinase-1 overexpression, but not aerobic exercise training, affects the development of diabetic nephropathy in BTBR
    Everaert I; He J; Hanssens M; Stautemas J; Bakker K; Albrecht T; Zhang S; Van der Stede T; Vanhove K; Hoetker D; Howsam M; Tessier FJ; Yard B; Baba SP; Baelde HJ; Derave W
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1030-F1040. PubMed ID: 32150446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human carnosinase 1 overexpression aggravates diabetes and renal impairment in BTBR
    Qiu J; Albrecht T; Zhang S; Hauske SJ; Rodriguez-Niño A; Zhang X; Nosan D; Pastene DO; Sticht C; Delatorre C; van Goor H; Porubsky S; Krämer BK; Yard BA
    J Mol Med (Berl); 2020 Sep; 98(9):1333-1346. PubMed ID: 32803273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of carnosine and carnosinase-1 on diabetes-induced afferent arteriole vasodilation: implications for glomerular hemodynamics.
    Rodriguez-Niño A; Pastene DO; Hettler SA; Qiu J; Albrecht T; Vajpayee S; Perciaccante R; Gretz N; Bakker SJL; Krämer BK; Yard BA; van den Born J
    Am J Physiol Renal Physiol; 2022 Jul; 323(1):F69-F80. PubMed ID: 35635322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral anserine supplementation does not attenuate type-2 diabetes or diabetic nephropathy in BTBR ob/ob mice.
    Everaert I; Van der Stede T; Stautemas J; Hanssens M; van Aanhold C; Baelde H; Vanhaecke L; Derave W
    Amino Acids; 2021 Aug; 53(8):1269-1277. PubMed ID: 34264387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium reduces blood glucose levels, but aggravates albuminuria in BTBR-ob/ob mice.
    de Groot T; Damen L; Kosse L; Alsady M; Doty R; Baumgarten R; Sheehan S; van der Vlag J; Korstanje R; Deen PMT
    PLoS One; 2017; 12(12):e0189485. PubMed ID: 29244860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-carnosine, a substrate of carnosinase-1, influences glucose metabolism.
    Sauerhöfer S; Yuan G; Braun GS; Deinzer M; Neumaier M; Gretz N; Floege J; Kriz W; van der Woude F; Moeller MJ
    Diabetes; 2007 Oct; 56(10):2425-32. PubMed ID: 17601992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term expression of glomerular genes in diabetic nephropathy.
    Chittka D; Banas B; Lennartz L; Putz FJ; Eidenschink K; Beck S; Stempfl T; Moehle C; Reichelt-Wurm S; Banas MC
    Nephrol Dial Transplant; 2018 Sep; 33(9):1533-1544. PubMed ID: 29340699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1.
    Janssen B; Hohenadel D; Brinkkoetter P; Peters V; Rind N; Fischer C; Rychlik I; Cerna M; Romzova M; de Heer E; Baelde H; Bakker SJ; Zirie M; Rondeau E; Mathieson P; Saleem MA; Meyer J; Köppel H; Sauerhoefer S; Bartram CR; Nawroth P; Hammes HP; Yard BA; Zschocke J; van der Woude FJ
    Diabetes; 2005 Aug; 54(8):2320-7. PubMed ID: 16046297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
    Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
    J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy.
    Waasdorp M; Florquin S; Duitman J; Spek CA
    FASEB J; 2019 Oct; 33(10):10966-10972. PubMed ID: 31287960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.
    Lavoz C; Matus YS; Orejudo M; Carpio JD; Droguett A; Egido J; Mezzano S; Ruiz-Ortega M
    Kidney Int; 2019 Jun; 95(6):1418-1432. PubMed ID: 30982673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diet containing cod backbone proteins attenuated the development of mesangial sclerosis and tubular dysfunction in male obese BTBR ob/ob mice.
    O'Keeffe M; Oterhals Å; Weishaupt H; Leh S; Ulvik A; Ueland PM; Halstensen A; Marti HP; Gudbrandsen OA
    Eur J Nutr; 2023 Dec; 62(8):3227-3240. PubMed ID: 37550593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.
    Hudkins KL; Li X; Holland AL; Swaminathan S; Alpers CE
    Nephrol Dial Transplant; 2022 Apr; 37(5):847-859. PubMed ID: 34865099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy.
    Hudkins KL; Pichaiwong W; Wietecha T; Kowalewska J; Banas MC; Spencer MW; Mühlfeld A; Koelling M; Pippin JW; Shankland SJ; Askari B; Rabaglia ME; Keller MP; Attie AD; Alpers CE
    J Am Soc Nephrol; 2010 Sep; 21(9):1533-42. PubMed ID: 20634301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
    Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
    Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
    Hudkins KL; Wietecha TA; Steegh F; Alpers CE
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus.
    Mallipattu SK; Gallagher EJ; LeRoith D; Liu R; Mehrotra A; Horne SJ; Chuang PY; Yang VW; He JC
    Am J Physiol Renal Physiol; 2014 May; 306(9):F1008-17. PubMed ID: 24598803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.